Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.
Am J Kidney Dis. 2022 Sep;80(3):373-382. doi: 10.1053/j.ajkd.2022.01.428. Epub 2022 Mar 16.
RATIONALE & OBJECTIVE: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder of glyoxylate metabolism that results in early-onset kidney stone disease, nephrocalcinosis, and kidney failure. There is an unmet need for reliable markers of disease progression to test effectiveness of new treatments for patients with PH. In this study, we assessed the rate of estimated glomerular filtration rate (eGFR) decline across chronic kidney disease (CKD) glomerular filtration rate (GFR) categories (CKD G2-G5) in a cohort of patients with PH1.
Retrospective observational study.
SETTING & PARTICIPANTS: Patients with PH1 enrolled in the Rare Kidney Stone Consortium (RKSC) registry who did not have kidney failure at diagnosis and who had at least 2 eGFR values recorded from within 1 month of diagnosis until their last contact date or incident kidney failure event.
CKD GFR category, baseline patient and laboratory characteristics.
Annualized rate of eGFR decline.
Generalized estimating equations and linear regression were used to evaluate the associations between CKD GFR category, baseline patient and laboratory characteristics, and annual change in eGFR during follow-up.
Compared with the slope in CKD G2 (-2.3 mL/min/1.73 m per year), the mean annual eGFR decline was nominally steeper in CKD G3a (-5.3 mL/min/1.73 m per year) and statistically significantly more rapid in CKD G3b and G4 (-14.7 and -16.6 mL/min/1.73 m per year, respectively). In CKD G2, older age was associated with a more rapid rate of eGFR decline (P = 0.01). A common PH1-causing variant of alanine glyoxylate aminotransferase, a glycine to arginine substitution at amino acid 170 (G170R), appeared to be associated with less severe annual decline in eGFR.
Data at regular time points were not available for all patients due to reliance on voluntary reporting in a retrospective rare disease registry.
The eGFR decline was not uniform across CKD GFR categories in this PH1 population, with a higher rate of eGFR decline in CKD G3b and G4. Thus, CKD GFR category needs to be accounted for when analyzing eGFR change in the setting of PH1.
1 型原发性高草酸尿症(PH1)是一种糖异生代谢的常染色体隐性疾病,可导致早发性肾结石病、肾钙质沉着症和肾衰竭。由于缺乏可靠的疾病进展标志物,因此需要对新疗法进行临床试验,以评估其对 PH1 患者的有效性。本研究旨在评估原发性高草酸尿症 1 型(PH1)患者在慢性肾脏病(CKD)肾小球滤过率(GFR)各分期(CKD G2-G5)中,估算肾小球滤过率(eGFR)下降的速率。
回顾性观察性研究。
本研究纳入了罕见肾脏病石症联盟(RKSC)登记处中,未在诊断时发生肾衰竭且在诊断后 1 个月内至少有 2 次 eGFR 值记录的 PH1 患者。
CKD GFR 分期、基线患者和实验室特征。
eGFR 下降的年化速率。
使用广义估计方程和线性回归分析评估 CKD GFR 分期、基线患者和实验室特征与随访期间 eGFR 年变化之间的关系。
与 CKD G2 相比(每年下降 2.3 mL/min/1.73 m2),CKD G3a 中 eGFR 下降的平均年化斜率更陡峭(每年下降 5.3 mL/min/1.73 m2),且 CKD G3b 和 G4 中的 eGFR 下降更为迅速(每年分别下降 14.7 和 16.6 mL/min/1.73 m2)。在 CKD G2 中,年龄较大与 eGFR 下降速率较快相关(P=0.01)。丙氨酸糖异生氨基转移酶的一种常见致病变异,即 170 位氨基酸甘氨酸突变为精氨酸(G170R),似乎与 eGFR 年下降幅度较小有关。
由于依赖于回顾性罕见疾病登记处的自愿报告,并非所有患者都有定期时间点的数据。
在 PH1 人群中,各 CKD GFR 分期的 eGFR 下降并不均匀,CKD G3b 和 G4 中的 eGFR 下降率更高。因此,在分析 PH1 患者的 eGFR 变化时,需要考虑 CKD GFR 分期。